Key result
Multiplex PCR (mPCR) demonstrated a 95% deletion detection rate, making it a viable initial molecular diagnostic approach for dystrophinopathies in resource-limited settings.
Why the study?
The study was conducted to determine the frequency and distribution of DMD gene variants in Sri Lanka using mPCR followed by MLPA, and to compare them to international literature.
What is the frequency and distribution of DMD gene variants in suspected myopathy patients in Sri Lanka, and what is the diagnostic yield of mPCR compared to MLPA?
Observational (n=236)
Yes
What is the frequency and distribution of DMD gene variants in suspected myopathy patients in Sri Lanka, and what is the diagnostic yield of mPCR compared to MLPA?
mPCR has a 95% deletion detection rate for DMD gene variants, making it a viable and cost-effective initial diagnostic tool in resource-limited settings prior to using MLPA.
mPCR may serve as initial diagnostic tool in resource-limited settings; leaves open validation in prospective cohorts.
BACKGROUND: The phenotype of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) patients is determined by the type of DMD gene variation, its location, effect on reading frame, and its size. The primary objective of this investigation was to determine the frequency and distribution of DMD gene variants (deletions/duplications) in Sri Lanka through the utilization of a combined approach involving multiplex polymerase chain reaction (mPCR) followed by Multiplex Ligation Dependent Probe Amplification (MLPA) and compare to the international literature. The current consensus is that MLPA is a labor efficient yet expensive technique for identifying deletions and duplications in the DMD gene. METHODOLOGY: Genetic analysis was performed in a cohort of 236 clinically suspected pediatric and adult myopathy patients in Sri Lanka, using mPCR and MLPA. A comparative analysis was conducted between our findings and literature data. RESULTS: In the entire patient cohort (n = 236), mPCR solely was able to identify deletions in the DMD gene in 131/236 patients (DMD-120, BMD-11). In the same cohort, MLPA confirmed deletions in 149/236 patients [DMD-138, BMD -11]. These findings suggest that mPCR has a detection rate of 95% (131/138) among all patients who received a diagnosis. The distal and proximal deletion hotspots for DMD were exons 45-55 and 6-15. Exon 45-60 identified as a novel in-frame variation hotspot. Exon 45-59 was a hotspot for BMD deletions. Comparisons with the international literature show significant variations observed in deletion and duplication frequencies in DMD gene across different populations. CONCLUSION: DMD gene deletions and duplications are concentrated in exons 45-55 and 2-20 respectively, which match global variation hotspots. Disparities in deletion and duplication frequencies were observed when comparing our data to other Asian and Western populations. Identified a 95% deletion detection rate for mPCR, making it a viable initial molecular diagnostic approach for low-resource countries where MLPA could be used to evaluate negative mPCR cases and cases with ambiguous mutation borders. Our findings may have important implications in the early identification of DMD with limited resources in Sri Lanka and to develop tailored molecular diagnostic algorithms that are regional and population specific and easily implemented in resource limited settings.
No takes yet. Share an insight, caveat, or question.
Wijekoon et al. (2024) conducted an observational in Duchenne and Becker muscular dystrophy (Dystrophinopathies) (n=236). Multiplex PCR (mPCR) and Multiplex Ligation Dependent Probe Amplification (MLPA) was evaluated on Detection rate of DMD gene deletions. Multiplex PCR (mPCR) demonstrated a 95% deletion detection rate, making it a viable initial molecular diagnostic approach for dystrophinopathies in resource-limited settings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: